Liberisan

Cytisinicline, the active ingredient in Liberisan, is a Nicotinic acetylcholine receptor partial agonist presented as an oral formulation for oral use. It is indicated for smoking cessation and helps reduce nicotine cravings and withdrawal symptoms in adults who wish to quit tobacco use.

GNH USA supplies Liberisan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liberisan is a nicotinic receptor‑targeting agent used in the management of nicotine‑related disorders.

- Smoking cessation: assists patients in quitting tobacco by reducing cravings and withdrawal. - Nicotine dependence: supports reduction of daily nicotine intake and promotes abstinence. - Tobacco use disorder: helps achieve sustained tobacco‑free status in motivated individuals.

Adverse reactions may occur with Liberisan use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction: signs include rash, swelling, or difficulty breathing. - Mood changes: emergence of depression or anxiety symptoms.

Before initiating Liberisan, consider the following safety measures.

- Cardiovascular assessment: evaluate history of heart disease or hypertension. - Psychiatric review: screen for depression, anxiety, or other mental health conditions. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously. - Liver function monitoring: check hepatic enzymes if pre‑existing liver disease is present. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Cytisinicline may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Other nicotinic agonists: additive stimulation may increase side‑effects. - Strong CYP2A6 inhibitors: may raise plasma levels of Cytisinicline.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood‑pressure lowering effect. - Antidepressants (SSRIs/SNRIs): monitor for mood alterations. - Warfarin: observe INR values for potential anticoagulation changes.